Bedaquiline
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
| - | Bedaquiline, sold under the brand name Sirturo, is a medication used to treat active tuberculosis.[ | + | Bedaquiline, sold under the brand name Sirturo, is a medication used to treat active tuberculosis.<ref name="a1">[https://www.drugs.com/monograph/bedaquiline.html "Bedaquiline Fumarate".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref> Specifically, it is used to treat multi-drug-resistant tuberculosis (MDR-TB) along with other medications for tuberculosis.<ref name="a1">[https://www.drugs.com/monograph/bedaquiline.html "Bedaquiline Fumarate".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref><ref name="a5">PMID:10903938</ref><ref name="a6">PMID:10903938</ref>[1][5][6 See also [https://en.wikipedia.org/wiki/Bedaquiline Bedaquiline]. |
[[4v1f]]. | [[4v1f]]. | ||
Revision as of 12:31, 28 December 2023
| |||||||||||
References
- ↑ 1.0 1.1 "Bedaquiline Fumarate". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- ↑ Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grutter MG. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000 Jul;7(7):493-504. PMID:10903938
- ↑ Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grutter MG. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000 Jul;7(7):493-504. PMID:10903938
